

Old Dominion University

ODU Digital Commons

Chemistry & Biochemistry Faculty Publications

Chemistry & Biochemistry

1-2020

Antibiotic Drug Nanocarriers for Probing of Multidrug ABC Membrane Transporter of *Bacillus subtilis*

Pavan Kumar Cherukuri

Preeyaporn Songkiatisak

Feng Ding

Jeam-Michel Jault

Xiao-Hong Nancy Xu

Follow this and additional works at: https://digitalcommons.odu.edu/chemistry_fac_pubs



Part of the [Biochemistry Commons](#), [Chemistry Commons](#), and the [Molecular Biology Commons](#)

Antibiotic Drug Nanocarriers for Probing of Multidrug ABC Membrane Transporter of *Bacillus subtilis*

Pavan Kumar Cherukuri,[§] Preeyaporn Songkiatisak,[§] Feng Ding,[§] Jean-Michel Jault, and Xiao-Hong Nancy Xu*



Cite This: *ACS Omega* 2020, 5, 1625–1633



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Multidrug membrane transporters can extrude a wide range of substrates, which cause multidrug resistance and ineffective treatment of diseases. In this study, we used three different sized antibiotic drug nanocarriers to study their size-dependent inhibitory effects against *Bacillus subtilis*. We functionalized 2.4 ± 0.7 , 13.0 ± 3.1 , and 92.6 ± 4.4 nm silver nanoparticles (Ag NPs) with a monolayer of 11-amino-1-undecanethiol and covalently linked them with antibiotics (ofloxacin, Ofx). The labeling ratios of antibiotics with NPs are 8.6×10^2 , 9.4×10^3 , and 6.5×10^5 Ofx molecules per NP, respectively. We designed cell culture medium in which both BmrA and Δ BmrA cells grew and functioned normally while ensuring the stabilities of nanocarriers (nonaggregation). These approaches allow us to quantitatively study the dependence of their inhibitory effect against two isogenic strains of *B. subtilis*, WT (normal expression of BmrA) and Δ BmrA (deletion of *bmrA*), upon the NP size, antibiotic dose, and BmrA expression. Our results show that the inhibitory effects of nanocarriers highly depend on NP size and antibiotic dose. The same amount of Ofx on 2.4 ± 0.7 , 13.0 ± 3.1 , and 92.6 ± 4.4 nm nanocarriers shows the 3 \times lower, nearly the same, and 10 \times higher inhibitory effects than that of free Ofx, against both WT and Δ BmrA, respectively. Control experiments of the respective sized AgMUNH₂ NPs (absence of Ofx) show insignificant inhibitory effects toward both strains. Taken together, the results show multiple factors, such as labeling ratios, multivalent effects, and pharmacodynamics (Ofx localization and distribution), which might play the roles in the size-dependent inhibitory effects on the growth of both WT and Δ BmrA strains. Interestingly, the inhibitory effects of nanocarriers are independent of the expression of BmrA, which could be attributed to the higher efflux of nanocarriers by other membrane transporters in both strains.



INTRODUCTION

ATP-binding cassette (ABC) membrane transporters are one of the largest membrane transport superfamilies, and they exist in all living organisms and play highly significant roles in biological functions.^{1–7} The ABC membrane transporters can selectively transport a wide variety of substrates across cellular membranes, even though they share a common modular architecture, two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs). TMDs exhibit variable sequence and topology and define substrate binding sites and transport passageway, while the NBDs possess conserved sequences and bind and hydrolyze ATP to provide the “power-stroke” for the transporters to translocate the specific substrates across the cellular membrane.^{7–17} The multidrug ABC membrane transporters can extrude chemotherapeutic agents out of bacteria or tumor cells, which causes multidrug resistance (MDR) and ineffective treatment of diseases, underscoring the importance of understanding their underlying mechanisms to design more effective therapy.^{3,18–22}

Bacillus subtilis (a Gram-positive bacterium) is a widely used model organism to study multidrug ABC transporters. Current studies show that there are 78 ABC transporters in *B.*

subtilis.^{23–25} BmrA (YvcC), the ABC transporter of *B. subtilis*, exhibits the highest homology to each half of P-gps (MDR1), HorA (40% identity), and LmrA (42% identity), which makes it an excellent choice to study multidrug ABC transporters.²⁶ Fluoroquinolones (e.g., Ofx, norfloxacin, ciprofloxacin, levofloxacin, and gemifloxacin) are widely used antibiotics to treat a variety of respiratory and urinary tract infections, which include pneumonia, chronic bronchitis, and tuberculosis.^{27,28} The extensive use of conventional antibiotics has led to the development of multiantibiotics resistance and the creation of superbugs that cannot be effectively eradicated by traditional antibiotics; hence, there is an urgent need to design new types of antibiotics and unconventional drugs (e.g., nanomedicine) to treat the infections.

Noble metal nanoparticles (NPs) possess unique physicochemical properties. Their high surface-area-to-volume ratio

Received: November 1, 2019

Accepted: December 31, 2019

Published: January 13, 2020






Figure 1. Chemical reactions for the preparation of antibiotic drug nanocarriers (AgMUNH–Oflx NPs): attaching monolayer of 11-amino-1-undecanethiol onto the surface of (A) 2.4 ± 0.7 , (B) 13.0 ± 3.1 , and (C) 92.6 ± 4.4 nm NPs to prepare AgMUNH₂ NPs and then linking the amine group of 11-amino-1-undecanethiol with the carboxyl group of the Oflx via peptide bonds using 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC) and sulfo-*N*-hydroxysulfosuccinimide (NHS) as mediators to generate AgMUNH–Oflx NPs (antibiotic drug nanocarriers).³⁰

allows them to serve as effective drug carriers that offer high payloads, high permeability, high local target concentrations, and high binding affinity due to multivalence effects.^{29–31} Furthermore, the high surface-area-to-volume ratio of NPs could also lead to high chemical reactivity, and bare NPs themselves could serve as unconventional drugs to eradicate bacteria.^{29,31–33} In our previous studies, we found that Ag and Au NPs at low concentrations do not inhibit cell growth and are biocompatible, while a higher concentration of NPs was unstable in the buffer or medium, which led to the aggregation of bare NPs on the surface of the cellular membrane that causes cell death.^{30,32–40}

We have successfully imaged single Ag NPs in solution, in single live cells, and single embryos and used their size-dependent plasmonic optical properties to study size-dependent efflux functions of multidrug membrane transporters in single live cells (both Gram-positive and Gram-negative bacteria) in real time at nanometer resolution.^{33–36,38–51} We have also used their size-dependent plasmonic optical properties to characterize the mode of action of antibiotics, such as aztreonam and chloramphenicol, in single live *Pseudomonas aeruginosa* cells.^{37,40} Therefore, the plasmonic NP-based drug carriers can serve as size-dependent photostable-sized imaging probes to study size-dependent efflux kinetics of multidrug membrane transporters and size-dependent MDR *in situ* in real time, while nanocarriers are inhibiting the bacterial growth.

In our previous study, we have designed, synthesized, purified, and characterized three different sized antibiotic nanocarriers and developed cell culture medium, in which *P. aeruginosa* (Gram-negative bacteria) cells grew and functioned normally and the nanocarriers remained unchanged (stable, nonaggregated).³⁰ We found that their inhibitory effect against two strains of *P. aeruginosa*, WT (normal expression of MexAB-OprM) and Δ ABM (deletion of MexAB-OprM),

highly depends upon the NP size, antibiotic dose, and multidrug membrane transporter (MexAB-OprM) expression. In this study, we used the same nanocarriers to study the dependence of inhibitory effect of the antibiotic nanocarriers against Gram-positive bacteria, two strains of *B. subtilis* (Gram-positive bacteria), WT (normal expression of BmrA) and Δ BmrA (deletion of *bmrA*), upon the size of nanocarriers, and dose of antibiotics (Oflx). Note that MexAB-OprM and BmrA are two completely different types of multidrug membrane transporters, energized by proton gradients across the cellular membrane and ATP hydrolysis, respectively. Further, *P. aeruginosa* are Gram-negative bacteria, while *B. subtilis* are Gram-positive bacteria, and they have very different cellular envelop structures. By comparing these two studies, we aim to understand the dependence of inhibitory effects of nanocarriers upon the types of multidrug membrane transporters and the types of bacteria.

RESULTS AND DISCUSSION

Synthesis, Purification, and Characterization of Stable Drug Nanocarriers. We synthesized, purified, and characterized 2.4 ± 0.7 , 13.0 ± 3.1 , and 92.6 ± 4.4 nm Ag NPs. We used the thiol group of 11-amino-1-undecanethiol hydrochloride (AUT) to attach a monolayer of AUT (MUNH₂) onto surface of NPs to prepare AgMUNH₂ NPs (Figure 1), as reported previously.³⁰ We then used a peptide bond to covalently conjugate the carboxyl group of Oflx with the amine group of AgMUNH₂ NPs to synthesize antibiotic drug nanocarriers (AgMUNH–Oflx) (Figure 1).³⁰

We purified the drug nanocarriers using centrifugation. We then characterized the sizes of the NPs, AUT (MUNH₂) on the NPs, and conjugation ratios of Oflx molecules per NP for 2.4 ± 0.7 , 13.0 ± 3.1 , and 92.6 ± 4.4 nm NPs as 8.6×10^2 , 9.4×10^3 , and 6.5×10^5 using transmission electron microscopy

and dynamic light scattering (DLS), NMR, and UV–vis spectroscopy, respectively.³⁰

We used DLS and UV–vis spectroscopy to study the stability (nonaggregation) of antibiotic drug nanocarriers with desired concentrations in a commonly used standard Lysogeny broth (LB) medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl in deionized (DI) water, pH = 7.2) in the shaker (MaxQ 5000, 200 rpm, 37 °C) for 12 h. We found that they were aggregated.³⁰ The aggregation of nanocarriers would alter their sizes and cause potential precipitation of nanocarriers from the medium that would reduce their doses and make the study of dose- and size-dependent unreliable. Therefore, we modified the cell culture medium by reducing the NaCl concentration from 0.5 to 0.1% and found that the drug nanocarriers with desired concentrations in the modified LB medium (1% tryptone, 0.5% yeast extract, and 0.1% NaCl in DI water, pH = 7.2) were stable (nonaggregated) under the cell culture condition and duration, in the shaker (MaxQ 5000, 200 rpm, 37 °C) for 12 h.

Characterization of Cellular Functions in the Modified Medium. We characterized the viability and efflux function of the cells cultured in the modified medium to make certain that the modified cell culture medium can be used to culture healthy and well-functional cells as those cultured in the standard cell culture medium. We precultured the cells (WT-BmrA and Δ BmrA) in the standard medium for 12 h, then cultured the precultured cells in the standard medium and the modified medium, and followed the cell growth over time. The growth curves of the cells cultured in the standard medium (Figure 2a) and the modified medium (Figure 2b) for WT (Figure 2A) and Δ BmrA (Figure 2B) are the same, showing that the cells grow normally in the modified cell culture medium.




Figure 2. Study of the suitability of the modified LB medium to culture (A) WT and Δ BmrA: the cellular growth curves of (A) WT and (B) Δ BmrA cultured in (a) standard and (b) modified LB media over time show that the growth rates of a given strain in either medium are nearly identical, which indicates that the modified LB medium can be used to culture both WT and Δ BmrA cells.

We then used live/dead BacLight assay to determine the viability of the cells, which had been cultured in the standard and modified media over 17 h. For live/dead BacLight assay,⁵² green fluorescent dye (SYTO9, $\lambda_{\text{max}} = 520$ nm) stains only live cells, while a red fluorescent dye (propidium iodide, $\lambda_{\text{max}} = 610$ nm) can only diffuse into the dead cells because of disintegrated cellular membranes of dead cells. Thus, the live cells exhibit green fluorescent, while dead cells display red fluorescent. The results in Figure 3 show that more than 97%




Figure 3. Study of the viability of the cells (WT and Δ BmrA) cultured in (a) standard and (b) modified LB medium using live/dead BacLight assay. (A) Optical and (B) fluorescence images of the cells (e.g., WT) that were cultured over 12 h and suspended in the phosphate-buffered saline (PBS) buffer and assayed using live/dead BacLight assay. The cells exhibiting green fluorescence and red fluorescence are counted as live and dead cells, respectively. (C) Plot of the percent of the live cells (number of live cells divided by the total number of the cells) cultured in (a) standard and (b) modified LB media shows that more than 97% of the cells (WT and Δ BmrA) are viable, which further demonstrates that the modified LB medium can be used to culture the cells. The scale bar is 5 μm .

of the cells cultured in both media over time exhibit SYTO9 green fluorescence, which demonstrates that 97% of the cells are viable. The results further demonstrate that the cells (BmrA and Δ BmrA) cultured in the modified medium grow normally and they are viable.

To characterize the efflux function of multidrug BmrA transporters of live cells, we studied the BmrA-dependent efflux kinetics of intracellular Hoechst dye (Hoechst 33342) in both WT and Δ BmrA live cells using fluorescence spectroscopy.^{39,51,53–57} Hoechst dye molecules emit weak fluorescent outside the cells, and their fluorescence intensity increases up to 10-folders as they enter the cells and intercalate with DNA.^{26,58} Thus, the time course fluorescence intensity of the dyes can be used to study their accumulation kinetics inside live cells in real time. The fluorescence intensity of the dyes incubated with Δ BmrA (absence of BmrA) increases with time more rapidly (Figure 4b) than those of WT (Figure 4a), showing that the efflux of the dye molecules out of the WT cells leads to a lower accumulation of intracellular dye




Figure 4. Characterization of the efflux function of membrane transporter (BmrA) in WT and Δ BmrA cells cultured in (A) standard and (B) modified LB medium. Time-dependent fluorescence intensity of 2 μ M Hoechst dye incubated with the cells ($OD_{600\text{ nm}} = 0.1$ in PBS buffer, pH 7.2): (a) WT and (b) Δ BmrA cultured in (A) standard and (B) modified LB media show nearly identical accumulation and efflux kinetics, demonstrating that the cells cultured in the modified LB medium possess well-functional efflux pump and the modified LB medium can be used to culture the cells for the study of accumulation and efflux kinetics of *B. subtilis*.

molecules in the WT than in Δ BmrA cells. The results show the high BmrA-dependent efflux kinetics of intracellular dye in live cells that were cultured in both standard and modified cell culture media (Figure 4A,B), respectively. The efflux kinetics of cells cultured in the standard medium (Figure 4A) are similar to those cells cultured in the modified medium, further demonstrating that the modified cell culture medium is well suitable to culture WT and Δ BmrA cells that preserve the efflux function of multidrug BmrA membrane transporters.

Study of Antibiotic Dose, NP Size, and BmrA Expression-Dependent Inhibitory Effects. We measured minimal inhibitory concentration (MIC) of Ofloxacin (Oflox) attached onto the nanocarriers to determine whether inhibitory effects of antibiotic nanocarriers against the growth of WT-BmrA and Δ BmrA depend on the NP size, Oflox dose, and BmrA expression. The cells (WT or Δ BmrA) were cultured in the modified LB medium containing a dilution series of free Oflox alone, each type of the given sized drug nanocarriers (AgMUNH–Oflox NPs) and AgMUNH₂ NPs (absence of Oflox, control experiment), and the cell growth was measured over time.

The dilution series contains 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μ M of free Oflox (Figure 5A,E) or Oflox carried by the NPs (AgMUNH–Oflox NPs) for WT-BmrA (Figure 5B–D) and Δ BmrA (Figure 5F–H), respectively. The corresponding concentrations of nanocarriers (NP concentration) are (Figure 5B: a–f) 0, 0.06, 0.13, 0.26, 0.49, and 0.83 nM for (2.4 \pm 0.7) nm NPs with a conjugation ratio of 8.6×10^2 Oflox molecules per NP; (Figure 5C: a–f) 0, 5.8×10^{-3} , 1.2×10^{-2} , 2.3×10^{-2} ,




Figure 5. Study of the dependence of inhibitory effects of antibiotic nanocarriers (AgMUNH–Oflox NPs) against the growth of (A–D) WT and (E–H) Δ BmrA cells upon antibiotic dose, NP size, and BmrA expression. Photographs of the LB medium cultured with (A–D) the WT cells and (E–H) Δ BmrA containing (a–f) 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μ M of (A and E) unconjugated free Oflox alone; (a–f) 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μ M of the Oflox conjugated with the Ag NPs of (B and F) 2.4 ± 0.7 , (C and G) 13.0 ± 3.1 , and (D and H) 92.6 ± 4.4 nm in diameters, respectively. The concentrations of Oflox conjugated onto the NPs are determined using their labeling ratios. The blank control experiments include the concentrations of AgMUNH₂ NPs in (a) of (B–D and F–H) containing 0.83 nM, 7.6×10^{-2} nM, or 1.1 pM AgMUNH₂ NPs (in the absence of Oflox) for 2.4 ± 0.7 , 13.0 ± 3.1 , or 92.6 ± 4.4 nm NPs, which are the same concentrations of the NPs of nanocarriers as those in (f) for each type of NPs (B–D and F–H), respectively.

4.5×10^{-2} , and 7.6×10^{-2} nM for (13.0 \pm 3.1) nm NPs with a conjugation ratio of 9.4×10^3 Oflox molecules per NP; (Figure 5D: a–f) 0, 8.4×10^{-5} , 1.7×10^{-4} , 3.4×10^{-4} , 6.4×10^{-4} , and 1.1×10^{-3} nM for (92.6 \pm 4.4) nm NPs with a conjugation ratio of 6.5×10^5 Oflox molecules per NP, respectively. The control experiments include the cells cultured with the LB medium alone (blank control, Figure 5A,E: a) or the medium containing 0.83, 7.6×10^{-2} , or 1.1×10^{-3} nM AgMUNH₂ NPs (in the absence of Oflox, Figure 5B–H: a) for the (2.4 \pm 0.7), (13.0 \pm 3.1), or (92.6 \pm 4.4) nm NPs, respectively. The control experiments were conducted in parallel with the experiments with antibiotic nanocarriers and at the same conditions.

We quantitatively measured the cell concentration over time by measuring their $OD_{600\text{ nm}}$ (optical density at 600 nm) at 5, 11, and 17 h, as shown in Figures S1 and S2 in the Electronic Online Supporting Information. Since nanocarriers and NPs possess plasmonic optical properties and molecular absorption at visible wavelengths, we subtracted the $OD_{600\text{ nm}}$ of the nanocarriers or AgMUNH₂ NPs in the medium (in the absence of the cells) from the $OD_{600\text{ nm}}$ of the cell suspension with the nanocarriers or NPs to determine the cell concentration, respectively. The subtracted $OD_{600\text{ nm}}$ of the cell suspension was plotted over time to determine the duration (17 h) for the cell growth to reach equilibrium. The $OD_{600\text{ nm}}$ of the cell suspension at 17 h was then plotted versus

the concentration of Ofx alone or Ofx covalently conjugated with a given sized antibiotic drug nanocarrier to determine the MIC of Ofx for each cell strain (Figure 6). The result shows that the inhibitory effects of Ofx highly depend on the dose of Ofx and size of the nanocarriers but not on the cellular expression of BmrA.




Figure 6. Study of dose-, size-, and BmrA-dependent MICs of antibiotic nanocarriers (AgMUNH–Ofx NPs) against (A) WT and (B) Δ BmrA cells. Plots of normalized OD_{600 nm} of the cells cultured for 17 h in the modified LB medium containing (a–c) AgMUNH₂ NPs (absence of Ofx, control), (d) Ofx alone, and (e–g) Ofx linked with (e) 2.4 ± 0.7 , (f) 13.0 ± 3.1 , and (g) 92.6 ± 4.4 nm Ag NPs, respectively. The concentrations of AgMUNH₂ NPs in (a–c) of (A) and (B) are the same as the given sized nanocarriers with the highest Ofx concentrations in (e–g) for each type of NPs in (A) and (B), but without Ofx (control experiments for the study of effects of NPs), respectively. The experimental data (points) are fitted with an equation $y = a e^{-bx}$, solid line as follows: (A): (d) $y = 1.12 e^{-5.02x}$, $R^2 = 0.918$; (e) $y = 1.10 e^{-1.964x}$, $R^2 = 0.841$; (f) $y = 1.11 e^{-6.53x}$, $R^2 = 0.881$; (g) $y = 1.00 e^{-55.48x}$, $R^2 = 1.000$. (B): (d) $y = 1.12 e^{-4.55x}$, $R^2 = 0.922$; (e) $y = 1.10 e^{-1.59x}$, $R^2 = 0.712$; (f) $y = 1.09 e^{-7.09x}$, $R^2 = 0.906$; (g) $y = 1.00 e^{-52.01x}$, $R^2 = 1.000$. The MICs (IC₅₀) of free Ofx and linked Ofx were determined at the half of the maximum of the normalized OD_{600 nm} for each curve (solid line).

Control experiments (Figure 6: a–c) show that the OD_{600 nm} of the cell suspension incubated with each of three different sized AgMUNH₂ NPs (absence of Ofx) are nearly independent on the NP concentration and nearly the same as those cultured in the medium alone. The result indicates that the given concentration of AgMUNH₂ NPs does not generate significant inhibitory effects against the growth of WT and Δ BmrA cells. Note that the NP concentration is the same as that of the highest concentration of the given sized nanocarriers, respectively. The studies have shown that the bare noble metal NPs (Ag NPs) themselves can inhibit the growth of bacteria in a concentration-dependent manner.^{32,59,60} Notably, the NPs that are functionalized with the surface molecules (e.g., peptides) exhibit biocompatibility of

the surface molecules, instead of the bare NPs.^{41,45,61} Thus, the biocompatibility of AgMUNH₂ NPs that we observed in the study is most likely attributed to the surface functional molecules (MUNH₂) that are attached on the surface of the NPs.

On the contrary, the OD_{600 nm} of the cell suspension incubated with Ofx alone or Ofx attached onto the given sized nanocarriers decrease as Ofx concentration increases, showing that their inhibitory effects against the growth of WT and Δ BmrA cells highly depend upon the dose of Ofx and size of nanocarriers (Figure 6A,B: d–f). We fitted the experimental data with an exponential decay equation ($y = a e^{-bx}$), which represents the inhibitory effect upon the exponential cell growth. We define the concentration of Ofx needed to reduce the growth of the cells in the medium alone to the half as the MIC of Ofx. The results of MICs are summarized in Table 1,

Table 1. Study of Dependence of MIC of Ofx upon the Size of Nanocarriers and Expression of BmrA of Two Strains of *B. subtilis* (WT and Δ BmrA)

samples	MIC ₅₀ of Ofx (μ M) ^a	
	WT	Δ BmrA
free Ofx alone	0.16 ± 0.00	0.17 ± 0.02
nanocarriers (2.4 ± 0.7 nm)	0.40 ± 0.02	0.49 ± 0.03
nanocarriers (13.0 ± 3.1 nm)	0.12 ± 0.01	0.11 ± 0.01
nanocarriers (92.6 ± 4.4 nm)	0.012 ± 0.001	0.012 ± 0.001

^aThe experimental data was fitted using the exponential decay equation ($y = a e^{-bx}$) to determine the parameters (a and b) with the highest regression. The MIC of Ofx for each sample was determined at the half of the cell growth of the blank control experiment (Figure 6).

showing that the MICs of free Ofx and Ofx attached onto the nanocarriers highly depend upon the dose of Ofx and the size of nanocarriers but not the cellular expression of BmrA.

For free Ofx alone (Figure 6A,B: d), the OD_{600 nm} of the cell suspension decrease with the Ofx concentration, showing the MICs of 0.16 ± 0.00 and 0.17 ± 0.02 μ M Ofx for the WT and Δ BmrA cells, respectively.

Interestingly, for 2.4 ± 0.7 nm drug nanocarriers with a conjugation ratio of 8.6×10^2 Ofx molecules/NP (Figure 6A,B: e), the OD_{600 nm} of the cell suspension decrease with the Ofx concentration less rapidly than those of free Ofx and two other larger nanocarriers. Notably, for 13.0 ± 3.1 nm drug nanocarriers with a conjugation ratio of 9.4×10^3 Ofx molecules/NP (Figure 6A,B: f), the OD_{600 nm} of the cell suspension decreases with the Ofx concentration are nearly the same as those of free Ofx, showing the nearly identical inhibitory and MICs of 0.12 ± 0.01 and 0.11 ± 0.01 μ M Ofx for the WT and Δ BmrA cells, as those of free Ofx, respectively. For 92.6 ± 4.4 nm drug nanocarriers with a conjugation ratio of 6.5×10^5 Ofx molecules/NP (Figure 6A,B: g), the OD_{600 nm} of the cell suspension decrease with the Ofx concentration the most rapidly, showing the highest inhibitory effects and the lowest MICs of 0.012 ± 0.001 and 0.012 ± 0.001 μ M Ofx for the WT and Δ BmrA cells, respectively.

The MICs of either free Ofx or Ofx attached onto nanocarriers for WT-BmrA and Δ BmrA cells are the same, suggesting that either form of Ofx could be extruded out of the cells by other membrane transporters in both WT-BmrA and Δ BmrA. In other words, Ofx is not a specific substrate of

BmrA, and other membrane transporters are primary forces to extrude the Ofx out of the cells, which leads to the insignificant (or masked) contribution of BmrA and the BmrA-independent MICs of Ofx.

Comparison of Both Studies and Distinctive Findings. By comparing the results in this study with our previous study,³⁰ we found that Ofx attached onto the nanocarriers retains its efficacy (inhibitory effect) against both Gram-positive bacteria (*B. subtilis*) and Gram-negative bacteria (*P. aeruginosa*). Inhibitory effects of nanocarriers against both strains of bacteria highly depend upon the size of nanocarriers, further demonstrating that the closed-packed Ofx molecules on the NPs (multivalence) could increase local drug dose, enhance their binding affinity with the target, and offer higher potency against both *B. subtilis* and *P. aeruginosa*. Notably, the inhibitory effects of nanocarriers are not linearly proportional to their sizes. For example, the smallest antibiotic nanocarriers (2.4 ± 0.7 nm) show the lowest inhibitory effects and the highest MICs against both strains than free Ofx, while the mid-sized nanocarriers (13.0 ± 3.1 nm) display the nearly identical inhibitory effects and MICs as free Ofx, and the largest antibiotic nanocarriers (92.6 ± 4.4 nm) exhibit the highest inhibitory effects and the lowest MICs against both strains.

The primary difference between both studies is their inhibitory effects on two different types of the cells (*B. subtilis* and *P. aeruginosa*) and their dependence on the efflux pump. For the previous study,³⁰ the inhibitory effects of nanocarriers highly depend upon the expression of MexAB-OprM (multidrug membrane transporter) of *P. aeruginosa* (Gram-negative bacterium). In this study, they are independent upon the expression of BmrA (multidrug membrane transporter) of *B. subtilis* (Gram-positive bacterium). Therefore, the inhibitory effects of nanocarriers against bacteria show the selectivity, suggesting the possibility of using them as medicines. Notably, all three sized nanocarriers can enter *B. subtilis* (Gram-positive bacteria) and *P. aeruginosa* (Gram-negative bacteria), even though *B. subtilis* (Gram-positive bacteria) possess a very different envelop structure from *P. aeruginosa* (Gram-negative bacteria), suggesting potential common applications against bacteria. Further, the results demonstrate that antibiotic drug nanocarriers show specificity toward the given membrane transporters and their potentially wide utility against both Gram-positive and Gram-negative bacteria.

SUMMARY

In summary, we have successfully used three different sized antibiotic drug nanocarriers (AgMUNH–Ofx NPs) to study their size-dependent inhibitory effects against Gram-positive bacteria (*Bacillus subtilis*, WT-BmrA, and Δ BmrA). We have designed a modified cell culture medium, which enables the WT-BmrA and Δ BmrA cells to grow normally and the antibiotic drug nanocarriers to be stable (nonaggregated) in the medium over the entire duration of cell culture (17 h). Thus, the size and dose of nanocarriers remain unchanged during their incubation with the cells for 17 h, enabling us to study the size- and dose-dependent effects of the drug nanocarriers on the cell growth and efflux function of BmrA. Control experiments of three sized AgMUNH₂ NPs (absence of Ofx) show insignificant inhibitory effects toward WT-BmrA and Δ BmrA, which are likely attributed to the surface functional molecules (MUNH₂) attached onto the NPs. The significant findings include that (i) the largest nanocarriers

create the highest inhibitory effects, while the smallest nanocarriers generate the lowest inhibitory effects, demonstrating that the same number of antibiotic molecules (Ofx) that are carried and delivered by the larger NPs can produce the higher inhibitory effects. These results indicate that the closed-packed Ofx molecules on the surface of NPs might strengthen their binding affinity with the target (multivalence) and provide larger payload to increase local targeting dose, leading to the higher potency. (ii) The inhibitory effects of Ofx depend upon the multivalent local targeting effects, as well as their intracellular distribution and concentrations. (iii) Their inhibitory effects do not significantly depend upon the cellular expression of multidrug BmrA membrane transporter, suggesting that other transporters in Δ BmrA could effectively extrude the antibiotic nanocarriers out of the Δ BmrA cells, leading to the same MICs as WT-BmrA. These findings show that the inhibitory effects of nanocarriers are not linearly proportional to their sizes, suggesting the possibility for one to design the optimal-sized nanocarriers to create the most potent effect of antibiotics against a specific given bacterial strain and to potentially evade a specific given multidrug membrane transporter. Efforts are being made to identify the specific membrane transporters that are responsible for the extrusion of drug nanocarriers out of WT-BmrA and Δ BmrA cells and to study their underlying molecular mechanisms.

MATERIALS AND METHODS

Characterization of Cell Culture. We used two strains of Gram-positive bacterial cells (*B. subtilis*): WT (normal expression BmrA) and Δ BmrA previously named as Δ YvcC (a mutant strain that is devoid of the *bmrA*, also named as Δ yvcC or Δ bmrA) that were isogenic strains and provided by Jault.²⁶ The cells were first precultured in a commonly used standard LB medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl in DI water, pH = 7.2) in a shaker (MaxQ 5000, 200 rpm, 37 °C) for 12 h. The precultured cells (20 μ L) were then further cultured in the 2 mL standard LB medium or the modified LB medium (1% tryptone, 0.5% yeast extract, and 0.1% NaCl in DI water, pH = 7.2) in a shaker (MaxQ 5000, 200 rpm, 37 °C) for another 17 h. The cell growth curves were determined by measuring the OD_{600 nm} of cell suspension in the medium over 17 h of cell culture. The cell suspension was diluted to the OD_{600 nm} of cell suspension below 0.2 and measured.

By the end of cell culture, we used live/dead BacLight viability and counting assay (Invitrogen) to assay the viability of the cultured cells.⁵² We used dark-field optical microscopy and epi-fluorescence microscopy to image the cells in a microchamber containing the medium.^{33,37,39,40,53} We acquired the green and red fluorescence cell images and counted them as live and dead cells, respectively.

By the end of the cell culture, we used centrifugation to harvest the cells (Beckman JA-14, 7500 rpm) and rinsed the cells with the PBS buffer (0.5 mM phosphate buffer, 1.5 mM NaCl, pH 7.0) three times. We suspended the cells in the PBS buffer and adjusted to a desired cell suspension concentration (OD_{600 nm} = 0.1) in the buffer. We continuously measured the fluorescence intensity of Hoechst 3342 dye (Invitrogen) of the cell suspension (OD_{600 nm} = 0.1) containing 2 μ M of the dye at a 3 s time interval for 2 h using a fluorescence spectrometer (PerkinElmer LS50B) with the excitation and emission wavelengths at 350 and 488 nm, respectively.

Synthesis, Purification, and Characterization of Drug Nanocarriers. We synthesized and characterized the antibiotic drug nanocarriers, as reported previously.³⁰ Briefly, we synthesized, purified, and characterized (2.4 ± 0.7), (13.0 ± 3.1), and (92.6 ± 4.4) nm Ag NPs, as reported previously.^{39,42,62} We used centrifugation to thoroughly wash the NPs three times with the DI water immediately after the synthesis. We used UV–vis spectroscopy (Hitachi U-2010), dark-field optical microscopy and spectroscopy (DFOMS), high-resolution transmission electron microscopy (JEOL, JEM-2100F), and dynamic light scattering (DLS) (Nicomp 380ZLS particle sizing system) to measure the NP concentrations, the LSPR images, the spectra of single NPs, and the sizes of single NPs, respectively.^{33,36,37,39,42–45,47,49,55,62} We used the inter-*action* of thiol groups of MUNH₂ with the NPs to attach 11-amino-1-undecanethiol hydrochloride (MUNH₂, AUT, 99%, Sigma-Aldrich) onto the surface of NPs to prepare functional AgMUNH₂ NPs. We used centrifugation (Beckman Optima L90k, 4 °C) to wash the AgMUNH₂ NPs thoroughly with DI water three times to remove excess MUNH₂. We used a two-step method via 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC) and *N*-hydroxysulfosuccinimide (*s*-NHS) as mediators to link the amine groups of each sized AgMUNH₂ NPs with the carboxyl group of Ofx via peptide bonds (Figure 1). We used centrifugation to wash the nanocarriers with DI water to purify the drug nanocarriers (AgMUNH–Ofx NPs) and stored them at 4 °C for future use. We used UV–vis spectroscopy, DFOMS, and DLS to characterize the concentrations, optical properties, and sizes of each sized AgMUNH₂ NPs, respectively.

We used UV–vis absorbance spectra of Ofx at 288 nm and the plasmonic absorption spectra of the NPs to measure the molar concentration of Ofx and NPs, respectively. We then divided the molar concentrations of Ofx molecules on the surface of the nanocarriers by the molar concentration of the NPs to determine the molar labeling ratios of antibiotics (Ofx) to NPs for each sized drug nanocarriers.³⁰

Study of Stability of Drug Nanocarriers in Cell Culture Medium. We used UV–vis absorption spectroscopy, DLS, and dark-field optical microscopy and spectroscopy to characterize the concentration, size, and optical properties of nanocarriers and studied their stability (nonaggregation) in the commonly used standard LB medium and the modified medium over 24 h, respectively. We found that the given concentrations of 2.4 ± 0.7 , 13.0 ± 3.1 , and 92.6 ± 4.4 nm nanocarriers (6.0 nM, 0.8 nM, and 7 pM) are stable (nonaggregated) in the modified medium over 24 h, but they are unstable (aggregated) in the standard medium.³⁰

Characterization of Dose- and Size-Dependent Inhibitory Effects of Nanocarriers. The cells (WT or Δ BmrA) were precultured in the standard LB medium overnight and then cultured in the modified LB medium (2.5 mL) containing a dilution series of free Ofx alone, given sized drug nanocarriers (AgMUNH–Ofx NPs), and AgMUNH₂ NPs (control experiments) by inoculating 10⁴ precultured cells into the medium in a shaker (200 rpm, 37 °C) over 17 h.

The dilution series of 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μ M free Ofx or Ofx conjugated with the NPs (AgMUNH–Ofx NPs) were prepared in the modified cell culture medium to culture WT and Δ BmrA (Figure 5). They are correlated with the drug nanocarrier (NP) concentrations: (i) 0, 0.06, 0.13, 0.26, 0.49, and 0.83 nM for (2.4 ± 0.7) nm NPs with a

conjugation ratio of 8.6×10^2 Ofx molecules per NP; (ii) 5.8×10^{-3} , 1.2×10^{-2} , 2.3×10^{-2} , 4.6×10^{-2} , and 7.6×10^{-2} nM for (13.0 ± 3.1) nm NPs with a conjugation ratio of 9.4×10^3 Ofx molecules per NP; and (iii) 8.4×10^{-2} , 1.7×10^{-1} , 3.4×10^{-1} , 6.4×10^{-1} , and 1.11 pM for (92.6 ± 4.4) nm NPs with a conjugation ratio of 6.5×10^5 Ofx molecules per NP. The control experiments include the modified LB medium only (blank control) and containing 0.83 nM, 7.6×10^{-2} nM, or 1.1 pM AgMUNH₂ NPs (in the absence of Ofx) for 2.4 ± 0.7 , 13.0 ± 3.1 , or 92.6 ± 4.4 nm NPs, respectively.

We quantitatively determined the OD_{600 nm} of the cell suspension in a 96-well plate using a plate reader (BioTek Synergy HT) equipped with a UV–vis absorption spectral detector at 5, 11, and 17 h. We plotted the OD_{600 nm} of the cell suspension vs time to determine the duration (17 h) for the cells to reach the confluence. We then used the plots of the OD_{600 nm} of each cell suspension at 17 h versus Ofx concentration (free Ofx or Ofx attached onto the nanocarrier) to determine their inhibitory effects (MIC). Specifically, we normalized the OD_{600 nm} of each cell suspension with the maximum OD_{600 nm} (the cells cultured in the medium alone, blank control), respectively. We plotted the normalized OD_{600 nm} of the cell suspension versus the concentration of free Ofx (Ofx alone) or the concentration of Ofx attached onto a given sized drug nanocarrier. We used the exponential decay ($y = a e^{-bx}$) to fit the experimental data and to determine the parameters (a, b) of the equation with the highest possible regression. The MIC₅₀ (the concentration of Ofx at which the cell growth was inhibited to the half of the cell growth of the blank control experiment) was then determined. Unlike conventional semiquantitative methods to estimate the MICs using solid culture plates (a colony-forming unit), we developed this new approach to quantitatively determine the MIC₅₀ using the dilution series of antibiotics or antibiotic nanocarriers in the liquid LB medium and mathematically fitting the experimental data. Further, the dilution series of antibiotics in the liquid LB medium enabled the nanocarriers to be well dispersed and avoided the aggregation of nanocarriers in the solid culture plates and allowed us to characterize the stability of nanocarriers in the liquid medium in real time at single NP resolution.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.9b03698>.

Growth curve of WT-BmrA cells incubated with (A) free Ofx, (B) 2.4 ± 0.7 , (C) 13.0 ± 3.1 , and (D) 92.6 ± 4.4 nm Ofx nanocarriers, and AgMUNH₂ NPs (in the absence of Ofx, control experiment) (Figure S1); and growth curve of Δ BmrA cells incubated with (A) free Ofx, (B) 2.4 ± 0.7 , (C) 13.0 ± 3.1 , and (D) 92.6 ± 4.4 nm Ofx nanocarriers, and AgMUNH₂ NPs (in the absence of Ofx, control experiment) (Figure S2) (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Xiao-Hong Nancy Xu – Old Dominion University, Norfolk, Virginia; orcid.org/0000-0002-7470-1948; Phone: (757) 683-5698; Email: xhxu@odu.edu; www.odu.edu/~xhxu

Other Authors

Pavan Kumar Cherukuri – Old Dominion University,
Norfolk, Virginia

Preeyaporn Songkiatisak – Old Dominion University,
Norfolk, Virginia

Feng Ding – Old Dominion University, Norfolk, Virginia;
 orcid.org/0000-0001-8739-4337

Jean-Michel Jault – UMR5086 CNRS/UCBLyon I,
MMSB-IBCP, Lyon, France

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsomega.9b03698>

Author Contributions

[§]P.K.C., P.S., and F.D. contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported, in part, by NSF (CBET 0507036 and 1450936) and NIH (R01 GM0764401, R21HL127580, and R15GM119116). All work was done in the Xu Lab. J.-M.J. provided Δ BmrA (also called as Δ yvcC or Δ bmrA) cells and discussion. The authors thank Tao Huang for participating in the synthesis and characterization of nanocarriers.

REFERENCES

- (1) Horsey, A. J.; Cox, M. H.; Sarwat, S.; Kerr, I. D. The multidrug transporter ABCG2: still more questions than answers. *Biochem. Soc. Trans.* **2016**, *44*, 824–830.
- (2) Higgins, C. F. ABC transporters: from microorganisms to man. *Annu. Rev. Cell Biol.* **1992**, *8*, 67–113.
- (3) Robey, R. W.; Pluchino, K. M.; Hall, M. D.; Fojo, A. T.; Bates, S. E.; Gottesman, M. M. Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat. Rev. Cancer* **2018**, *18*, 452–464.
- (4) Schumacher, T.; Benndorf, R. A. ABC Transport Proteins in Cardiovascular Disease-A Brief Summary. *Molecules* **2017**, *22*, 589.
- (5) Cole, S. P.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science* **1992**, *258*, 1650–1654.
- (6) Grube, M.; Hagen, P.; Jedlitschky, G. Neurosteroid Transport in the Brain: Role of ABC and SLC Transporters. *Front Pharmacol.* **2018**, *9*, 354.
- (7) Verhalen, B.; Dastvan, R.; Thangapandian, S.; Peskova, Y.; Koteiche, H. A.; Nakamoto, R. K.; Tajkhorshid, E.; Mchaourab, H. S. Energy transduction and alternating access of the mammalian ABC transporter P-glycoprotein. *Nature* **2017**, *543*, 738–741.
- (8) Gottesman, M. M.; Ambudkar, S. V.; Xia, D. Structure of a multidrug transporter. *Nat. Biotechnol.* **2009**, *27*, 546–547.
- (9) Higgins, C. F. ABC transporters: physiology, structure and mechanism—an overview. *Res. Microbiol.* **2001**, *152*, 205–210.
- (10) Hung, L. W.; Wang, I. X.; Nikaido, K.; Liu, P. Q.; Ames, G. F.; Kim, S. H. Crystal structure of the ATP-binding subunit of an ABC transporter. *Nature* **1998**, *396*, 703–707.
- (11) Locher, K. P.; Lee, A. T.; Rees, D. C. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. *Science* **2002**, *296*, 1091–1098.
- (12) Davidson, A. L.; Chen, J. ATP-binding cassette transporters in bacteria. *Annu. Rev. Biochem.* **2004**, *73*, 241–268.
- (13) Holland, I. B.; Blight, M. A. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. *J. Mol. Biol.* **1999**, *293*, 381–399.
- (14) Dawson, R. J.; Locher, K. P. Structure of a bacterial multidrug ABC transporter. *Nature* **2006**, *443*, 180–185.
- (15) Higgins, L. K. The ATP switch model for ABC transporters. *Nat. Struct. Mol. Biol.* **2004**, *11*, 918–926.
- (16) Jones, P. M.; George, A. M. Mechanism of the ABC transporter ATPase domains: catalytic models and the biochemical and biophysical record. *Crit. Rev. Biochem. Mol. Biol.* **2013**, *48*, 39–50.
- (17) Mishra, S.; Verhalen, B.; Stein, R. A.; Wen, P. C.; Tajkhorshid, E.; Mchaourab, H. S. Conformational dynamics of the nucleotide binding domains and the power stroke of a heterodimeric ABC transporter. *elife* **2014**, *3*, e0274.
- (18) Cole, S. P. Multidrug resistance protein 1 (MRP1, ABCC1), a “multitasking” ATP-binding cassette (ABC) transporter. *J. Biol. Chem.* **2014**, *289*, 30880–30888.
- (19) Nigam, S. K. What do drug transporters really do? *Nat. Rev. Drug Discovery* **2015**, *14*, 29–44.
- (20) Fletcher, J. I.; Williams, R. T.; Henderson, M. J.; Norris, M. D.; Haber, M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. *Drug Resist. Updates* **2016**, *2*, 1–9.
- (21) McIntosh, K.; Balch, C.; Tiwari, A. K. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells. *Exp. Opin. Drug Metab. Toxicol.* **2016**, *12*, 633–644.
- (22) Trowitzsch, S.; Tampé, R. ABC Transporters in Dynamic Macromolecular Assemblies. *J. Mol. Biol.* **2018**, *430*, 4481–4495.
- (23) Aguilar, C.; Vlamakis, H.; Losick, R.; Kolter, R. Thinking about *Bacillus subtilis* as a multicellular organism. *Curr. Opin. Microbiol.* **2007**, *10*, 638–643.
- (24) Quentin, Y.; Fichant, G.; Denizot, F. Inventory, assembly and analysis of *Bacillus subtilis* ABC transport systems. *J. Mol. Biol.* **1999**, *287*, 467–484.
- (25) Völker, U.; Hecker, M. From genomics via proteomics to cellular physiology of the Gram-positive model organism *Bacillus subtilis*. *Cell Microbiol.* **2005**, *7*, 1077–1085.
- (26) Steinfels, E.; Orelle, C.; Fantino, J. R.; Dalmas, O.; Rigaud, J. L.; Denizot, F.; Di Pietro, A.; Jault, J. M. Characterization of YvcC (BmrA), a multidrug ABC transporter constitutively expressed in *Bacillus subtilis*. *Biochemistry* **2004**, *43*, 7491–7502.
- (27) Paton, J. H.; Reeves, D. S. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. *Drugs* **1988**, *36*, 193–228.
- (28) Marslin, G.; Revina, A. M.; Khandelwal, V. K.; Balakumar, K.; Sheeba, C. J.; Franklin, G. PEGylated ofloxacin nanoparticles render strong antibacterial activity against many clinically important human pathogens. *Colloids Surf., B* **2015**, *132*, 62–70.
- (29) Baptista, P. V.; McCusker, M. P.; Carvalho, A.; Ferreira, D. A.; Mohan, N. M.; Martins, M.; Fernandes, A. R. Nano-Strategies to Fight Multidrug Resistant Bacteria—“A Battle of the Titans”. *Front Microbiol.* **2018**, *9*, 1441.
- (30) Ding, F.; Songkiatisak, P.; Cherukuri, P. K.; Huang, T.; Xu, X. Size-Dependent Inhibitory Effects of Antibiotic Drug Nanocarriers against *Pseudomonas aeruginosa*. *ACS Omega* **2018**, *3*, 1231–1243.
- (31) Natan, M.; Banin, E. From Nano to Micro: using nanotechnology to combat microorganisms and their multidrug resistance. *FEMS Microbiol. Rev.* **2017**, *41*, 302–322.
- (32) Kyriacou, S. V. *Real-time Study of Multidrug Resistance Mechanism in Pseudomonas aeruginosa Using Nanoparticle Optics and Single Live Cell Imaging*; Old Dominion University: Norfolk, VA, 2003.
- (33) Xu, X.-H. N.; Chen, J.; Jeffers, R. B.; Kyriacou, S. V. Direct measurement of sizes and dynamics of single living membrane transporters using nano-optics. *Nano Lett.* **2002**, *2*, 175–182.
- (34) Browning, L. M.; Lee, K. J.; Cherukuri, P. K.; Huang, T.; Songkiatisak, P.; Warren, S.; Xu, X. Single gold nanoparticle plasmonic spectroscopy for study of chemical-dependent efflux function of single ABC transporters of single live *Bacillus subtilis* cells. *Analyst* **2018**, *143*, 1599–1608.
- (35) Browning, L. M.; Lee, K. J.; Cherukuri, P. K.; Huang, T.; Warren, S.; Xu, X.-H. N. Single nanoparticle plasmonic spectroscopy for study of charge-dependent efflux function of multidrug ABC transporters of single live *Bacillus subtilis* cells. *J. Phys. Chem. C* **2016**, *120*, 21007–21016.

- (36) Browning, L. M.; Lee, K. J.; Cherukuri, P. K.; Nallathamby, P. D.; Warren, S.; Jault, J.-M.; Xu, X.-H. N. Single nanoparticle plasmonic spectroscopy for study of efflux function of multidrug ABC membrane transporters of single live cells. *RSC Adv.* **2016**, *6*, 36794–36802.
- (37) Kyriacou, S. V.; Brownlow, W. J.; Xu, X. H. N. Using nanoparticle optics assay for direct observation of the function of antimicrobial agents in single live bacterial cells. *Biochemistry* **2004**, *43*, 140–147.
- (38) Lee, K. J.; Browning, L. M.; Huang, T.; Ding, F.; Nallathamby, P. D.; Xu, X.-H. N. Probing of multidrug ABC membrane transporters of single living cells using single plasmonic nanoparticle optical probes. *Anal. Bioanal. Chem.* **2010**, *397*, 3317–3328.
- (39) Nallathamby, P. D.; Lee, K. J.; Desai, T.; Xu, X.-H. N. Study of multidrug membrane transporters of single living pseudomonas aeruginosa cells using size-dependent plasmonic nanoparticle optical probes. *Biochemistry* **2010**, *49*, 5942–5953.
- (40) Xu, X.-H. N.; Brownlow, W. J.; Kyriacou, S. V.; Wan, Q.; Viola, J. J. Real-time probing of membrane transport in living microbial cells using single nanoparticle optics and living cell imaging. *Biochemistry* **2004**, *43*, 10400–10413.
- (41) Huang, T.; Browning, L. M.; Xu, X.-H. N. Far-field photostable optical nanoscopy (PHOTON) for real-time super-resolution single-molecular imaging of signaling pathways of single live cells. *Nanoscale* **2012**, *4*, 2797–2812.
- (42) Huang, T.; Nallathamby, P. D.; Gillet, D.; Xu, X.-H. N. Design and synthesis of single nanoparticle optical biosensors for imaging and characterization of single receptor molecules on single living cells. *Anal. Chem.* **2007**, *79*, 7708–7718.
- (43) Browning, L. M.; Lee, K. J.; Huang, T.; Nallathamby, P. D.; Lowman, J.; Xu, X.-H. N. Random walk of single gold nanoparticles in zebrafish embryos leading to stochastic toxic effects on embryonic developments. *Nanoscale* **2009**, *1*, 138–152.
- (44) Lee, K. J.; Browning, L. M.; Nallathamby, P. D.; Desai, T.; Cherukuri, P.; Xu, X.-H. N. In vivo quantitative study of size-dependent transport and toxicity of single silver nanoparticles using zebrafish embryos. *Chem. Res. Toxicol.* **2012**, *25*, 1029–1046.
- (45) Lee, K. J.; Nallathamby, P. D.; Browning, L. M.; Osgood, C. J.; Xu, X.-H. N. In vivo imaging of transport and biocompatibility of single silver nanoparticles in early development of zebrafish embryos. *ACS Nano* **2007**, *1*, 133–143.
- (46) Lee, K. J.; Nallathamby, P. D.; Browning, L. M.; Desai, T.; Cherukuri, P.; Xu, X.-H. N. Single nanoparticle spectroscopy for real-time in vivo quantitative analysis of transport and toxicity of single nanoparticles in single embryos. *Analyst* **2012**, *137*, 2973–2986.
- (47) Nallathamby, P. D.; Lee, K. J.; Xu, X.-H. N. Design of stable and uniform single nanoparticle photonics for in vivo dynamics imaging of nanoenvironments of zebrafish embryonic fluids. *ACS Nano* **2008**, *2*, 1371–1380.
- (48) Nallathamby, P. D.; Xu, X.-H. N. Study of cytotoxic and therapeutic effects of stable and purified silver nanoparticles on tumor cells. *Nanoscale* **2010**, *2*, 942–952.
- (49) Nallathamby, P. D.; Huang, T.; Xu, X.-H. N. Design and characterization of optical nano rulers of single nanoparticles using optical microscopy and spectroscopy. *Nanoscale* **2010**, *2*, 1715–1722.
- (50) Xu, X.-H. N. Far-Field Photostable Optical Nanoscopy (PHOTON). In *Encyclopedia of Spectroscopy and Spectrometry*, 3rd ed.; Lindon, J., Tranter, G. E., Koppelaar, D., Eds.; Elsevier: Oxford, 2017; Vol. 1, pp 566–570.
- (51) Xu, X.-H. N.; Song, Y.; Nallathamby, P. D. Probing Membrane Transport of Single Live Cells Using Single Molecule Detection and Single Nanoparticle Assay. In *New Frontiers in Ultrasensitive Bioanalysis: Advanced Analytical Chemistry Applications in Nanobiotechnology, Single Molecule Detection, and Single Cell Analysis*; Xu, X.-H. N., Ed.; Wiley: NJ, 2007; pp 41–65.
- (52) Berney, M.; Hammes, F.; Bosshard, F.; Weilenmann, H. U.; Egli, T. Assessment and Interpretation of Bacterial Viability By Using The LIVE/DEAD Baclight Kit In Combination With Flow Cytometry. *Appl. Environ. Microbiol.* **2007**, *73*, 3283–3290.
- (53) Kyriacou, S. V.; Nowak, M. E.; Brownlow, W. J.; Xu, X.-H. N. Single live cell imaging for real-time monitoring of resistance mechanism in pseudomonas aeruginosa. *J. Biomed. Opt.* **2002**, *7*, 576–586.
- (54) Ocaktan, A.; Yoneyama, H.; Nakae, T. Use of fluorescence probes to monitor function of the subunit proteins of the MexA-MexB-OprM drug extrusion machinery in Pseudomonas aeruginosa. *J. Biol. Chem.* **1997**, *272*, 21964–21969.
- (55) Xu, X.-H. N.; Brownlow, W. J.; Huang, S.; Chen, J. Real-time measurements of single membrane pump efficiency of single living pseudomonas aeruginosa cells using fluorescence microscopy and spectroscopy. *Biochem. Biophys. Res. Commun.* **2003**, *305*, 79–86.
- (56) Xu, X.-H. N.; Wan, Q.; Kyriacou, S. V.; Brownlow, W. J.; Nowak, M. E. Direct observation of substrate induction of resistance mechanism in Pseudomonas aeruginosa using single live cell imaging. *Biochem. Biophys. Res. Commun.* **2003**, *305*, 941–949.
- (57) Ding, F.; Lee, K. J.; Vahedi-Faridi, A.; Yoneyama, H.; Osgood, C. J.; Xu, X. H. N. Design and study of the efflux function of the EGFP fused MexAB-OprM membrane transporter in Pseudomonas aeruginosa using fluorescence spectroscopy. *Analyst* **2014**, *139*, 3088–3096.
- (58) Cosa, G.; Focsaneanu, K.-S.; McLean, J. R. N.; McNamee, J. P.; Scaiano, J. C. Photophysical properties of fluorescent DNA-dyes bound to single- and double-stranded DNA in aqueous buffered solution. *Photochem. Photobiol.* **2001**, *73*, 585–599.
- (59) Nisar, P.; Ali, N.; Rahman, L.; Ali, M.; Shinwari, Z. K. Antimicrobial activities of biologically synthesized metal nanoparticles: an insight into the mechanism of action. *J. Biol. Inorg. Chem.* **2019**, *27*, 927.
- (60) Lv, D.; Wang, R.; Tang, G.; Mou, Z.; Lei, J.; Han, J.; De Smedt, S.; Xiong, R.; Huang, C. Ecofriendly Electrospun Membranes Loaded with Visible-Light-Responding Nanoparticles for Multifunctional Usages: Highly Efficient Air Filtration, Dye Scavenging, and Bactericidal Activity. *ACS Appl. Mater. Interfaces* **2019**, *11*, 12880–12889.
- (61) Lee, K. J.; Browning, L. M.; Nallathamby, P. D.; Xu, X. H. N. Study of charge-dependent transport and toxicity of peptide-functionalized silver nanoparticles using zebrafish embryos and single nanoparticle plasmonic spectroscopy. *Chem. Res. Toxicol.* **2013**, *26*, 904–917.
- (62) Huang, T.; Nallathamby, P. D.; Xu, X. H. N. Photostable Single-molecule Nanoparticle Optical Biosensors for Real-time Sensing of Single Cytokine Molecules and their Binding Reactions. *J. Am. Chem. Soc.* **2008**, *130*, 17095–17105.